Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody. Lunsumio is approved in the EU for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
Lunsumio is a first-in-class fixed-duration CD20xCD3 T-cell engaging bispecific antibody. Lunsumio is approved in more than 50 countries, including the EU and the US, for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.